Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis

Ann C. Kroksveen, Jacob D. Jaffe, Elise Aasebø, Harald Barsnes, Yngvild Bjørlykke, Diego Franciotta, Hasmik Keshishian, Kjell Morten Myhr, Jill A. Opsahl, Vincent van Pesch, Charlotte E. Teunissen, Øivind Torkildsen, Rune J. Ulvik, Heidrun Vethe, Steven A. Carr, Frode S. Berven

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS with unknown cause. Proteins with different abundance in the cerebrospinal fluid (CSF) from relapsing-remitting MS (RRMS) patients and neurological controls could give novel insight to the MS pathogenesis and be used to improve diagnosis, predict prognosis and disease course, and guide in therapy decisions. We combined iTRAQ labeling and Orbitrap mass spectrometry to discover proteins with different CSF abundance between six RRMS patients and 18 neurological disease controls. From 777 quantified proteins seven were selected as biomarker candidates, namely chitinase-3-like protein 1, secretogranin-1 (Sg1), cerebellin-1, neuroserpin, cell surface glycoprotein MUC18, testican-2 and glutamate receptor 4. An independent sample set of 13 early-MS patients, 13 RRMS patients and 13 neurological controls was used in a multiple reaction monitoring verification study. We found the intracellular calcium binding protein Sg1 to be increased in early-MS patients compared to RRMS and neurological controls. Sg1 should be included in further studies to elucidate its role in the early phases of MS pathogenesis and its potential as a biomarker for this disease.

Original languageEnglish
Pages (from-to)3361-3369
Number of pages9
JournalProteomics
Volume15
Issue number19
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Chromogranins
Cerebrospinal fluid
Proteomics
Multiple Sclerosis
Cerebrospinal Fluid
Biomarkers
CD146 Antigens
Proteins
Disease control
Chitinases
Calcium-Binding Proteins
Membrane Glycoproteins
Glutamate Receptors
Relapsing-Remitting Multiple Sclerosis
Labeling
Mass spectrometry
Mass Spectrometry
Chronic Disease
Monitoring

Keywords

  • Biomarkers
  • Biomedicine
  • Cerebrospinal fluid
  • Multiple sclerosis
  • Quantitative mass spectrometry
  • Secretogranin-1

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. / Kroksveen, Ann C.; Jaffe, Jacob D.; Aasebø, Elise; Barsnes, Harald; Bjørlykke, Yngvild; Franciotta, Diego; Keshishian, Hasmik; Myhr, Kjell Morten; Opsahl, Jill A.; van Pesch, Vincent; Teunissen, Charlotte E.; Torkildsen, Øivind; Ulvik, Rune J.; Vethe, Heidrun; Carr, Steven A.; Berven, Frode S.

In: Proteomics, Vol. 15, No. 19, 01.10.2015, p. 3361-3369.

Research output: Contribution to journalArticle

Kroksveen, AC, Jaffe, JD, Aasebø, E, Barsnes, H, Bjørlykke, Y, Franciotta, D, Keshishian, H, Myhr, KM, Opsahl, JA, van Pesch, V, Teunissen, CE, Torkildsen, Ø, Ulvik, RJ, Vethe, H, Carr, SA & Berven, FS 2015, 'Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis', Proteomics, vol. 15, no. 19, pp. 3361-3369. https://doi.org/10.1002/pmic.201400142
Kroksveen, Ann C. ; Jaffe, Jacob D. ; Aasebø, Elise ; Barsnes, Harald ; Bjørlykke, Yngvild ; Franciotta, Diego ; Keshishian, Hasmik ; Myhr, Kjell Morten ; Opsahl, Jill A. ; van Pesch, Vincent ; Teunissen, Charlotte E. ; Torkildsen, Øivind ; Ulvik, Rune J. ; Vethe, Heidrun ; Carr, Steven A. ; Berven, Frode S. / Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. In: Proteomics. 2015 ; Vol. 15, No. 19. pp. 3361-3369.
@article{8d758afc6b4949b9a415f2aa59f8f6ec,
title = "Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis",
abstract = "Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS with unknown cause. Proteins with different abundance in the cerebrospinal fluid (CSF) from relapsing-remitting MS (RRMS) patients and neurological controls could give novel insight to the MS pathogenesis and be used to improve diagnosis, predict prognosis and disease course, and guide in therapy decisions. We combined iTRAQ labeling and Orbitrap mass spectrometry to discover proteins with different CSF abundance between six RRMS patients and 18 neurological disease controls. From 777 quantified proteins seven were selected as biomarker candidates, namely chitinase-3-like protein 1, secretogranin-1 (Sg1), cerebellin-1, neuroserpin, cell surface glycoprotein MUC18, testican-2 and glutamate receptor 4. An independent sample set of 13 early-MS patients, 13 RRMS patients and 13 neurological controls was used in a multiple reaction monitoring verification study. We found the intracellular calcium binding protein Sg1 to be increased in early-MS patients compared to RRMS and neurological controls. Sg1 should be included in further studies to elucidate its role in the early phases of MS pathogenesis and its potential as a biomarker for this disease.",
keywords = "Biomarkers, Biomedicine, Cerebrospinal fluid, Multiple sclerosis, Quantitative mass spectrometry, Secretogranin-1",
author = "Kroksveen, {Ann C.} and Jaffe, {Jacob D.} and Elise Aaseb{\o} and Harald Barsnes and Yngvild Bj{\o}rlykke and Diego Franciotta and Hasmik Keshishian and Myhr, {Kjell Morten} and Opsahl, {Jill A.} and {van Pesch}, Vincent and Teunissen, {Charlotte E.} and {\O}ivind Torkildsen and Ulvik, {Rune J.} and Heidrun Vethe and Carr, {Steven A.} and Berven, {Frode S.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/pmic.201400142",
language = "English",
volume = "15",
pages = "3361--3369",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "19",

}

TY - JOUR

T1 - Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis

AU - Kroksveen, Ann C.

AU - Jaffe, Jacob D.

AU - Aasebø, Elise

AU - Barsnes, Harald

AU - Bjørlykke, Yngvild

AU - Franciotta, Diego

AU - Keshishian, Hasmik

AU - Myhr, Kjell Morten

AU - Opsahl, Jill A.

AU - van Pesch, Vincent

AU - Teunissen, Charlotte E.

AU - Torkildsen, Øivind

AU - Ulvik, Rune J.

AU - Vethe, Heidrun

AU - Carr, Steven A.

AU - Berven, Frode S.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS with unknown cause. Proteins with different abundance in the cerebrospinal fluid (CSF) from relapsing-remitting MS (RRMS) patients and neurological controls could give novel insight to the MS pathogenesis and be used to improve diagnosis, predict prognosis and disease course, and guide in therapy decisions. We combined iTRAQ labeling and Orbitrap mass spectrometry to discover proteins with different CSF abundance between six RRMS patients and 18 neurological disease controls. From 777 quantified proteins seven were selected as biomarker candidates, namely chitinase-3-like protein 1, secretogranin-1 (Sg1), cerebellin-1, neuroserpin, cell surface glycoprotein MUC18, testican-2 and glutamate receptor 4. An independent sample set of 13 early-MS patients, 13 RRMS patients and 13 neurological controls was used in a multiple reaction monitoring verification study. We found the intracellular calcium binding protein Sg1 to be increased in early-MS patients compared to RRMS and neurological controls. Sg1 should be included in further studies to elucidate its role in the early phases of MS pathogenesis and its potential as a biomarker for this disease.

AB - Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS with unknown cause. Proteins with different abundance in the cerebrospinal fluid (CSF) from relapsing-remitting MS (RRMS) patients and neurological controls could give novel insight to the MS pathogenesis and be used to improve diagnosis, predict prognosis and disease course, and guide in therapy decisions. We combined iTRAQ labeling and Orbitrap mass spectrometry to discover proteins with different CSF abundance between six RRMS patients and 18 neurological disease controls. From 777 quantified proteins seven were selected as biomarker candidates, namely chitinase-3-like protein 1, secretogranin-1 (Sg1), cerebellin-1, neuroserpin, cell surface glycoprotein MUC18, testican-2 and glutamate receptor 4. An independent sample set of 13 early-MS patients, 13 RRMS patients and 13 neurological controls was used in a multiple reaction monitoring verification study. We found the intracellular calcium binding protein Sg1 to be increased in early-MS patients compared to RRMS and neurological controls. Sg1 should be included in further studies to elucidate its role in the early phases of MS pathogenesis and its potential as a biomarker for this disease.

KW - Biomarkers

KW - Biomedicine

KW - Cerebrospinal fluid

KW - Multiple sclerosis

KW - Quantitative mass spectrometry

KW - Secretogranin-1

UR - http://www.scopus.com/inward/record.url?scp=84942985688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942985688&partnerID=8YFLogxK

U2 - 10.1002/pmic.201400142

DO - 10.1002/pmic.201400142

M3 - Article

C2 - 26152395

AN - SCOPUS:84942985688

VL - 15

SP - 3361

EP - 3369

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 19

ER -